FindTrial
Sign In

Effect of Oxis on the Efficacy of Mucociliary Clearance in Patients with COPD

Effect of Oxis on the Efficacy of Mucociliary Clearance in Patients with COPD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-000366-39-DE
Enrollment
Unknown
Registered
2005-03-22
Start date
2005-04-14
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Trade Name: Oxis Product Name: Oxis Pharmaceutical Form: Inhalation powder INN or Proposed INN: Formoterolfumarat Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 12

Sponsors

Inamed Research GmbH & Co. KG
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with an established clinical diagnosis of COPD, severity I and IIa according to the GOLD guidelines FEV1 > 50 % pred FEV1/FVC =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Pregnancy and nursing Present asthma, positive prick test

Design outcomes

Primary

MeasureTime frame
Main Objective: The influence of different medications on mucociliary lung clearance will be investigated;Secondary Objective: not applicable;Primary end point(s): Particle retention after 2 hours—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026